Loading...

Pipeline

PORTFOLIO OF PRODUCT CANDIDATES

Product

ORTICUMAB (Atherosclerosis)

ORTICUMAB (psoriasis)

ORTICUMAB Lp(a)

AB-CE3

AB-JB7

AB-AH10

AB-SLP

AB-210

Research

Preclinical

Clinical

Unmet Need

Current anti-inflammatory immunomodulating drugs can effectively treat rheumatic diseases, but have serious side effects - including infections and cancers

  • Orticumab is a monoclonal antibody that works differently than current inflammation treatments by targeting OxLDL, a highly specific source of inflammation
  • Orticumab has been in 200+ patients and subjects with a pristine safety profile – no drug-related serious adverse events
  • Since Orticumab works by a more targeted mechanism, we do not expect it to suppress the immune system and cause infection. That makes it different than other systemic treatments for inflammatory diseases
  • Currently preparing for phase 2 trials in two indications 1) Plaque Psoriasis and 2) Accelerated atherosclerosis in rheumatology patients